Clinical Handbook of Psychotropic Drugs

Ric M. Procyshyn, Kalyna Z. Bezchlibnyk-Butler, David D. Kim (Herausgeber)

Buch | Spiralbindung

480 Seiten

2023 | 25. Auflage
Hogrefe Publishing (Verlag)
978-0-88937-632-8 (ISBN)

Artikel merken

The classic reference to psychotropic medications for psychiatrists, psychologists, physicians, pharmacists, and nurses, packed with the latest drugs, completely revised sections, and much more.

The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

Independent, unbiased, up-to-date
Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug
Potential interactions and side effects summarized in comparison charts
With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
Clearly written patient information sheets available for download as printable PDF files

This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

New in this edition:

Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion; Auvelity extended-release tablets)
Antipsychotics updates include revised Clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
Dementia chapter includes a new section on Lecanemab (Leqembi), a fast-track FDA approved treatment for Alzheimer's disease
Treatment of Substance Use Disorders includes revisions to Buprenorphine dosing section to include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetic chapters all substantially revised
New formulations and trade names include: Invega Hafyera (paliperidone long-acting 6-monthly IM injection), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)

Ric M. Procyshyn, BScPharm, MSc, PharmD, PhD, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada.

Kalyna Z. Bezchlibnyk-Butler, BScPharm, FCSHP, Toronto, ON, Canada.

David D. Kim, BSc, MSc, PhD, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.

Erscheinungsdatum	06.06.2023
Verlagsort	Toronto
Sprache	englisch
Maße	279 x 216 mm
Themenwelt	Geisteswissenschaften ► Psychologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie
	Pflege ► Fachpflege ► Neurologie / Psychiatrie
	Medizin / Pharmazie ► Pharmazie ► Apothekenpraxis
	Medizin / Pharmazie ► Pharmazie ► PTA / PKA
ISBN-10	0-88937-632-8 / 0889376328
ISBN-13	978-0-88937-632-8 / 9780889376328
Zustand	Neuware